SCHEMBL17269947

SCHEMBL17269947

CC1(C(=O)Nc2ccc(S)cc2)CCNCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KHK P50053 1/20 0.45
▸ CETP P11597 2/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ CYP1A2 P05177 2/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP3A4 P08684 2/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ NR2E3 Q9Y5X4 1/20 0.35
▸ DRD2 P14416 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HTR1E P28566 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ S1PR3 Q99500 1/20 0.34
▸ CNR1 P21554 1/20 0.34
▸ CNR2 P34972 1/20 0.34
▸ BACE1 P56817 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ NAMPT P43490 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20224882 0.84 CYP1A2 (0.52) KHKCETPHDAC1CYP1A2CYP2D6
SCHEMBL18474437 0.82 KHK (0.51) KHKHDAC1MAPTLMNA
SCHEMBL17269902 0.81 TGM2 (0.47) KHKHDAC1NAMPT
SCHEMBL27760911 0.76 NPSR1 (0.56) KHKHDAC1CYP3A4CYP2C19MAPT
SCHEMBL31058163 0.76 KHK (0.43) KHKHDAC1CYP1A2CYP2D6CYP3A4
SCHEMBL25775264 0.73 MAPT (0.53) CETPCYP3A4MAPTL3MBTL1POLB
SCHEMBL13696944 0.73 TDP1 (0.53) MAPTHTR1ENPSR1S1PR3POLB
SCHEMBL1446943 0.72 LIMK2 (0.53) KHKCYP2D6LMNA
SCHEMBL18530076 0.71 ALDH1A1 (0.52) HDAC1MAPTBACE1POLBLMNA
SCHEMBL18205875 0.71 L3MBTL1 (0.52) HDAC1MAPTNPSR1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015175171-A1 SUBSTITUTED N-(2-(AMINO)-2-OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES X-RX DISCOVERY, INC. (US) 2015-11-19 — — WO disclosed
Send feedback